ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2008 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 24, 2008--ImmunoGen, Inc. (Nasdaq: IMGN) will host a conference call at 4:30 p.m. ET on Thursday, January 31, 2008 to discuss the Company's financial results for the three-month period ended December 31, 2007 -- the second quarter of ImmunoGen's 2008 fiscal year. Management also will provide an update on the Company.
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be heard through the Investor Information section on the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through February 7, 2008.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Targeting Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing -- IMGN901 (huN901-DM1) and IMGN242 (huC242-DM4). Three TAP compounds are in clinical testing through ImmunoGen's collaborations with other companies -- AVE9633 and SAR3419, in development by sanofi-aventis, and T-DM1 (trastuzumab-DM1), in development by Genentech. Additionally, the naked antibody compound, AVE1642, is in clinical testing through the Company's collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through ImmunoGen's collaborations and internal programs.
CONTACT:
ImmunoGen, Inc.
Carol Hausner
Executive Director, Investor Relations and Corporate Communications
617-995-2500
info@immunogen.com
